MARSEILLEVIRUS: A GIANT VIRUS IN SEARCH OF DISEASE
In this issue of the Journal, Popgeorgiev et al report investigations stemming from deep sequencing to find DNA viruses too large to pass through ultrafilters typically used in virus hunting [1] . Their findings suggest the presence of a previously unknown virus in blood samples from asymptomatic French blood donors. They call the approximately 357-kb virus "giant blood Marseillevirus" (GBM) because of its close relationship to a Marseillevirus first isolated from Seine River water cocultivated with amoebae, within which it replicates. No Marseillevirus has to date been shown to cause disease, although one Marseilleviridae family member, Senegalvirus, has been isolated from feces of an asymptomatic person. The Marseilleviridae family is grouped within the nucleocytoplasmic large DNA viruses (NCLDVs), a diverse order. The largest member, mimivirus, has been found in a variety of protists and has a length of 1.18 Mb, making it the largest virus discovered to date. Members of the NCLDV range from familiar viruses that can infect humans and other vertebrates, such as those of the Poxviridae and Asfarviridae (the cause of African swine fever) families, respectively, to poorly understood viruses that seem to primarily infect insects, Paramecium, algae, or, as in the case of Marseilleviridae, amoebae. These viruses are unique both in size and genetic makeup, frequently including genes of a variety of viral, bacterial, and cellular origins, including protists. It has recently been proposed that the giant viruses, some of which also contain messenger RNA within their capsid, be reclassified as the Megaviridae and that they may even qualify as a fourth domain of life, beyond the Archaea, Bacteria, and Eukarya [2] .
The intriguing findings reported by Popgeorgiev et al include not only identifying GBM DNA in pooled blood specimens from 10 donors and tracing the source to a single donor, but also evidence of viral capsids, antigens, and antibody in that donor's serum, as well as evidence that the virus can replicate in the human Jurkat T-cell-derived cell line. Finally, the authors examined specimens from 20 further asymptomatic blood donors and found 3 to be seroreactive against antigen prepared from the related Marseillevirus, 2 of which were also polymerase chain reaction (PCR) positive for GBM.
While these findings must be confirmed independently, they suggest that this virus may well be part of what is increasingly called the human viromeviruses associated with people. Such interactions can involve the gamut of hostmicrobe relationships, ranging from no discernable infection; to acute infection, that may or may not result in disease, which may then either be cleared or, instead, result in persistent productive or latent infection; to becoming part of the human genome itself (as occurs with endogenous retroviruses). The findings that 4 of 30 apparently asymptomatic blood donors were seropositive and that, of these 4, 3 were also PCR positive, while preliminary and obtained by a serologic assay with a sensitivity and specificity that are not fully characterized, are suggestive of a reasonably common persistent or latent infection of generally low virulence. There are precedents for finding blood-borne viruses that, although widespread, do not appear to be pathogenic in humans, such as Torque Teno virus and its relatives, as well as GB virus C [3] . However, given the very preliminary state of knowledge about GBM, a potential role for this virus in causing human disease, whether acute or chronic or limited to certain individuals (eg, those who have a specific genetic background or are immunocompromised), should not be excluded and is important to study, including its implications for transfusion safety. So for now, like many other microbes discovered through random searching for "foreign" nucleic acids (as opposed to those found while trying to understand a disease), GBM remains a virus both in search of disease(s) and of its hosts.
GBM AND KEEPING BLOOD AND ORGAN DONATIONS SAFE
In addition to independent confirmation of GBM in asymptomatic blood donors, development of well-characterized serologic assays will be important. If the reported findings are confirmed, seroepidemiologic studies and PCR can more broadly and accurately determine the prevalence of antibodies, suggesting exposure, and the prevalence and duration of viral DNA in the blood, suggesting persistent or latent infection (which may be discriminated through expression profiling and other studies), and can define the age groups and populations in which infection is acquired and most common. Stored samples and prospective studies of blood and organ donors and donation recipients, before and after transfusion or transplantation, can help determine whether the virus is efficiently transmitted through blood and organs and, if so, whether there are associated clinical or laboratory manifestations. A multitude of other studies, including basic biologic analyses, such as which hosts, cells, and anatomic sites may be susceptible, the effects of such susceptibility, the potential development of animal models, and the search for GBM in association with unexplained diseases and disease states, will be of great interest. The finding that Jurkat cells may support GBM replication is tantalizing and, although certain nonlymphocytotrophic viruses (eg, enterovirus 71) can also grow in these cells, raises the possibility of GBM interacting with T cells and the potential for immune modulation.
Beyond such research studies, if GBM is found to cause acute or chronic disease and to also be transmissible by transfusion and/or transplantation, the development of tests to potentially screen donors must then be more fully pursued. In some instances, even if the criteria of disease causation and transmission are met but where infection is otherwise ubiquitous through other exposures and is typically asymptomatic or mild (eg, cytomegalovirus [CMV] infection), generalized blood screening may not be needed or cost-effective. However, if transfusion and/or transplantation of blood and organs obtained from GBM-positive donors was found to pose a significant health risk, it should be feasible to develop tests to screen donors. More understanding would be needed to determine whether testing for DNA, antibodies, or both is most appropriate. For example, in some circumstances nucleic acid testing (NAT) is indicated because only NAT-positive specimens pose an infectious risk (as in acute infections in which recovering individuals clear the virus, like West Nile virus) or because NAT is most sensitive, particularly early during infection, prior to development of antibodies (as seen with human immunodeficiency virus and hepatitis C virus). Whether NAT, antibody tests, or both were needed, there is ample precedent in recent years for rapid development, validation, and implementation of such tests [4] , which can often use existing platform technologies and are increasingly automated and able to support testing for multiple pathogens [5] . However, such tests must be very carefully developed and evaluated, because they must not only be highly sensitive, but also, given their use in screening millions of donations annually, highly specific so as to avoid false-positive results and the potential to reduce blood and organ availability. Thus, both costs and public health consequences are not insignificant in considering adding donor testing. As diagnostic tools advance, however, it may be possible to screen donors by multiplex arrays or other assays that sensitively detect either all known pathogens or selected pathogens of concern, and to even use the same technologies to concurrently identify the immune and infection status of recipients. This could further enable what can be thought of as "personalized transfusion",forexampleavoidingbloodtransfusion from pathogen-positive donors to pathogen-negative (ie non-immune) recipients, but allowing transfusion from positive donors to recipients who are already immune, provided such transfusion does not pose added risks. This approach is similar to the use of serologic testing to prevent transfusion of blood from CMV positive donors specifically to CMV negative immunocompromised recipients, individuals to whom it can pose a substantial risk.
THE HUMAN VIROME: DATA, KNOWLEDGE, AND THE WEB OF LIFE WITHIN Whether or not GBM turns out to be a significant pathogen, the findings from this study raise a number of fascinating and important general issues. First, the power of new science to detect potential pathogens as causes of currently undiagnosed illness or contributors to chronic disease is remarkable. Second, going from discovery of a microbe to a disease may, in many cases, be more challenging than traditional disease-based pathogen discovery. In addition, akin to the challenges associated with specialization in clinical medicine, as science becomes increasingly driven by data, noise-to-signal ratios can become high, and few individuals or groups may have the knowledge, perspective, and clinical and laboratory resources to place data in perspective to best understand how to respond. Third, our horizon, whether as clinicians, researchers, or patients, must be expanded to include the understanding that we are not simply organisms locked in battle with pathogens. As has become abundantly clear as we begin to understand the microbiomes in our skin, gut, genitourinary tract, and elsewhere, our own microbial world is constantly interacting, both among its members and with our immune and other cells, and these interactions, or their disequilibrium, are critical in causing, understanding, and treating certain diseases [6] . It is similarly likely that viruses, including many that billions of people live with for much of their lifespan, even when they do not cause a disease in the traditional sense, can interact with and affect our immune and inflammatory responses [7] . Whether GBM has such properties is unknown, but if so it could exert unique effects, whether deleterious or beneficial, based on its complement of genes of diverse origin. Whatever the conclusion to this story, just as there is a web of life and an ecosystem outside of us that we are all part of, so too is there one within and on us. These ecosystems can and do communicate, sometimes through microbes. Along with other recently appreciated influences, such as the epigenome and extracellular RNA, we clearly share pathogens and information across species and kingdoms of life. Such sharing poses both clear risks but also potential benefits, such as in our ability to better sense, respond, and adapt to our environments, thereby influencing health and disease.
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